Form 4 for PCVX Vaxcyte, Inc.
Accepted 2026-08-05 16:58:16 ET · period of report 2026-08-03 · accession 0001230724-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-05 16:58 | 2026-08-03 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $5.35 | +10.0K | 115.2K | +10% | +$53.5K |
| DMT | 2026-08-05 16:58 | 2026-08-03 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | S - Sale+OE | $53.89 | -10.0K | 105.2K | -9% | -$538.9K |
| DT | 2026-08-05 16:58 | 2026-08-03 | PCVX | GUGGENHIME ANDREW | Pres AND CFO | M - OptEx | $0.00 | -10.0K | 216.8K | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-03 | M | A | 10,000 | $5.35 | 115,176 | D | — | — | (F1) Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026. |
| 2 | Common | Common Stock | 2026-08-03 | S | D | 6,956 | $53.76 | 108,220 | D | — | — | (F2) The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026. (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $53.06 to $54.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2026-08-03 | S | D | 3,044 | $54.18 | 105,176 | D | — | — | (F2) The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026. (F4) The price reported is a weighted-average price. The shares were sold at prices ranging from $54.07 to $54.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 4 | Derivative | Stock Option (right to buy) | 2026-08-03 | M | D | 10,000 | $0.00 | 216,827 | D | $5.35 · — to 2030-05-11 | 10,000 Common Stock | (F6) Option is fully vested and exercisable. |